

Center for Infectious Diseases in accomplishing the part of its mission related to preparing recommendations for the prevention and control of all types of viral hepatitis and their

sequellae. In order to focus prevention efforts and resource allocation, a representative view of the overall burden of chronic liver disease, its natural history, and the relative

contribution of viral hepatitis is needed. The total cost to respondents is estimated at \$600.

Respondents	No. of respondents	No. of responses/ respondent	Average burden/ response (in hrs.)	Total burden (in hrs.)
All consenting adults with physician-diagnosed chronic liver disease residing in catchment area .....	120	1	0.50	60
Total .....				60

Dated: September 12, 1996.

Wilma G. Johnson,

*Acting Associate Director for Policy Planning and Evaluation Centers for Disease Control and Prevention (CDC).*

[FR Doc. 96-23863 Filed 9-17-96; 8:45 am]

BILLING CODE 4163-18-P

### Cabin Exposure Assessment for a Study of Reproductive Outcomes Among Female Flight Attendants; Meeting

The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) announces the following meeting.

*Name:* Cabin Exposure Assessment for a Study of Reproductive Outcomes Among Female Flight Attendants.

*Time and Date:* 9 a.m.-4 p.m., October 11, 1996.

*Place:* Alice Hamilton Laboratories, NIOSH, Conference Room C, 5555 Ridge Road, Cincinnati, Ohio 45213.

*Status:* Open to the public, limited only by the space available. The meeting room accommodates approximately 50 people.

*Purpose:* Invited participants will provide NIOSH with their individual advice and comments regarding the technical and scientific aspects of the study, "Cabin Exposure Assessment for a Study of Reproductive Outcomes Among Female Flight Attendants," being conducted at NIOSH. Participants on the peer review panel will review the study protocol and provide individual advice on the conduct of the study. Viewpoints and suggestions from industry, labor, academia, other government agencies, and the public are invited.

*Contact Person for Additional Information:* Martha Waters, Ph.D., NIOSH, CDC, M/S R-14, 4676 Columbia Parkway, Cincinnati, Ohio 45226, telephone 513/841-4458.

Dated: September 11, 1996.

Nancy C. Hirsch,

*Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).*

[FR Doc. 96-23866 Filed 9-17-96; 8:45 am]

BILLING CODE 4160-19-M

### Advisory Council for the Elimination of Tuberculosis: Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces the following council meeting.

*Name:* Advisory Council for the Elimination of Tuberculosis (ACET).

*Times and Dates:* 8:30 a.m.-5 p.m., October 9, 1996, 8:30 a.m.-1 p.m., October 10, 1996.

*Place:* Corporate Square Office Park, Corporate Square Boulevard, Building 11, Room 1413, Atlanta, Georgia 30329.

*Status:* Open to the public, limited only by the space available. The meeting room accommodates approximately 100 people.

*Purpose:* This council advises and makes recommendations to the Secretary of Health and Human Services, the Assistant Secretary for Health, and the Director, CDC, regarding the elimination of tuberculosis. Specifically, the Council makes recommendations regarding policies, strategies, objectives, and priorities; addresses the development and application of new technologies; and reviews the extent to which progress has been made toward eliminating tuberculosis.

*Matters To Be Discussed:* Agenda items will include an update on ACET's letter to the Secretary of the Department of Health and Human Services; discussion of interactions between rifamycins and protease inhibitors; a report on Isoniazid hepatitis; and a discussion on tuberculosis vaccine development.

Agenda items are subject to change as priorities dictate.

*Contact Person for More Information:* Connie Granoff, Program Specialist, National Center for HIV, STD, and TB Prevention, 1600 Clifton Road, NE, M/S E-07, Atlanta, Georgia 30333, telephone 404/639-8008.

Dated: September 11, 1996.

Nancy C. Hirsch,

*Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).*

[FR Doc. 96-23861 Filed 9-17-96; 8:45 am]

BILLING CODE 4163-18-M

### Food and Drug Administration

[Docket No. 96N-0166]

### Pasca Plasma Center, Inc.; Revocation of U.S. License No. 1015

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the revocation of the establishment license (U.S. License No. 1015) and the product license issued to Pasca Plasma Center, Inc., (Pasca) for the manufacture of Source Plasma. Pasca has facilities in Berkeley, Oakland, and Richmond, CA. In a letter to FDA dated July 7, 1993, Pasca submitted U.S. license No. 1015 for revocation.

**DATES:** The revocation of the establishment license (U.S. License No. 1015) and the product license became effective on August 4, 1993.

**FOR FURTHER INFORMATION CONTACT:** Valerie A. Windsor, Center for Biologics Evaluation and Research (HFM-630), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852-1448, 301-594-3074.

**SUPPLEMENTARY INFORMATION:** FDA has revoked the establishment license (U.S. License No. 1015) and the product license issued to Pasca at the following locations for the manufacture of Source Plasma: (1) 1796 University Ave., Berkeley, CA 94703 (U.S. License 1015-003); (2) 650 E. 14th St., Oakland, CA 94606 (U.S. License 1015-001); and (3) 2316 MacDonald Ave., Richmond, CA 94804 (U.S. License 1015-002). Pasca's mailing address is: 650 E. 14th St., Oakland, CA 94606.

FDA inspected Pasca's Richmond facility from December 1, 1992 through December 11, 1992, and its Oakland facility from March 22, 1993, through April 2, 1993. In addition to the inspections, FDA conducted investigations which included interviews with individuals